Literature DB >> 12360981

Warfarin treatment of a patient with coagulation factor IX propeptide mutation causing warfarin hypersensitivity.

Søren Risom Kristensen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12360981     DOI: 10.1182/blood-2002-06-1753

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  4 in total

Review 1.  Life-threatening bleeding under vitamin K antagonists in spite of an INR in the therapeutic range.

Authors:  Mathilde Gavillet; Claire Abbal; Sabine Schmidt; Jasmine Nötzli; Jean-François Lambert; Anne Angelillo-Scherrer
Journal:  J Thromb Thrombolysis       Date:  2011-08       Impact factor: 2.300

2.  Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study.

Authors:  Andrea L Jorgensen; Sameh Al-Zubiedi; Jieying Eunice Zhang; Andrew Keniry; Anita Hanson; Dyfrig A Hughes; Diane van Eker; Lisa Stevens; Karen Hawkins; Cheng H Toh; Farhad Kamali; Ann K Daly; David Fitzmaurice; Alison Coffey; Paula R Williamson; Brian Kevin Park; Panos Deloukas; Munir Pirmohamed
Journal:  Pharmacogenet Genomics       Date:  2009-10       Impact factor: 2.089

3.  Association of warfarin dose with genes involved in its action and metabolism.

Authors:  Mia Wadelius; Leslie Y Chen; Niclas Eriksson; Suzannah Bumpstead; Jilur Ghori; Claes Wadelius; David Bentley; Ralph McGinnis; Panos Deloukas
Journal:  Hum Genet       Date:  2006-10-18       Impact factor: 4.132

4.  Factor IX p.A37V mutation causes severe bleeding in a patient with phenprocoumon therapy.

Authors:  Nils Mülling; Vivian Rosery; H Christian Reinhardt; Maher Hanoun
Journal:  Eur J Med Res       Date:  2021-06-29       Impact factor: 2.175

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.